Tag: 5/8/26

Exercise Helps Hip Arthritis Pain, but Perhaps Less than We Thought

Photo by RDNE Stock project


A new Cochrane review finds that exercise may improve pain and function, but the benefits may fall short of what patients would notice in daily life.

Hip osteoarthritis is a condition affecting millions of people worldwide and a leading cause of chronic pain and disability. Exercise is widely recommended as a first-line treatment for managing hip arthritis pain.

Led by researchers from University of Sydney and University of Melbourne, the findings show exercise produces small improvements in pain and physical function for people with hip osteoarthritis, but those improvements may not be large enough to make a meaningful difference to patients.

The review included 18 clinical trials involving 1368 people. Participants were mostly women (63%) and were aged between 53 and 74 years, meaning findings may not apply to younger people. Exercise programmes in the included studies varied widely, lasting between two and 52 weeks and covering a range of types including strengthening, aerobic, and mind-body approaches.

Compared with no treatment or usual care, exercise probably reduces pain by around 7 points on a 100-point scale. However, experts generally consider an improvement of at least 12 points necessary for patients to notice a meaningful difference in daily life. Physical function showed a similar pattern. The authors note, however, that these thresholds were derived largely from knee and mixed osteoarthritis populations, and may not entirely reflect the hip osteoarthritis experience.

Quality of life, arguably the outcome patients care about most, showed little to no improvement with exercise regardless of the comparison used.
 

“Exercise is recommended as a primary treatment for hip osteoarthritis, and this review doesn’t overturn that, but it does suggest we should be honest with patients that the average benefit may be modest, and that we need better-designed trials to understand who benefits most and from which type of exercise.”

— Michelle Hall, co-lead author from the University of Sydney. 


This update analysed results differently from its 2014 predecessor, which pooled all available data together and found high-quality evidence that exercise slightly reduced pain. The new review separated trials according to what exercise was being compared against.

When exercise was tested against a placebo or sham treatment, the evidence for pain relief weakened considerably. And adding exercise on top of another treatment made little difference either. While no single type of exercise came out on top, the authors caution that the evidence to answer that question properly simply isn’t there yet.

Not a recommendation away from exercise

The review stops short of saying exercise is ineffective or should be abandoned as a recommendation. Exercise carries broad health benefits beyond arthritis, is low-cost, and is unlikely to cause harm. 

Most studies included in this review were small and unblinded, which may have influenced outcomes. Because pain and function were largely self-reported, and participants knew whether they were exercising, exercise may appear more effective than it truly is.

The authors call for larger, better-designed trials to give patients and clinicians a clearer picture of what exercise can realistically achieve for hip osteoarthritis specifically.
 

“There just isn’t a huge body of evidence out there. For some people struggling with hip pain, exercise can really be their only hope, but I also don’t want to give patients false hope. It’s important future research is done with larger, better-quality trials, examining what types of exercise work specifically for different people.” 

— Belinda Lawford, co-lead author from the University of Melbourne. 

Read the review

By Mia Parkinson

Source: Cochrane

Company Successfully Bioprints Kidney and Liver Tissues in Space

Weightlessness of space allows tissues to be bioprinted without collapsing

Bioprinted liver tissue
Bioprinted nerve implant

Auxilium Biotechnologies announced a major milestone in space biomanufacturing with the successful bioprinting of kidney and liver tissues aboard the International Space Station (ISS), marking the first time either tissue type has been manufactured in space. Auxilium’s bioprinted biological tissues and nerve repair implants returned to earth on Mission AXLM-3 that flew on a SpaceX capsule and returned to Earth on June 17th, 2026.

“Successfully bioprinting living liver & kidney tissue aboard the International Space Station marks an important step forward for regenerative medicine.” — Dr. Anthony Atala, MD, Professor & Director of the Wake Forest Institute for Regenerative MedicineShare

During the mission, Auxilium’s AMP-1 orbital bioprinter successfully manufactured kidney, liver, and cartilage tissues while also producing 28 nerve repair implants. The achievement represents the first demonstration of kidney tissue manufacturing in space, the first demonstration of liver tissue manufacturing in space, and the first mission to manufacture three distinct tissue types during a single spaceflight. The production of multiple tissue types and clinically relevant nerve repair implants represents the first demonstration of a scalable, multi-product biomanufacturing platform in space.

Equally important, the mission demonstrated the ability of a single autonomous manufacturing platform to produce both living tissues and implantable medical products during the same flight. The simultaneous production of multiple tissue types alongside 28 nerve repair implants highlights not only the versatility of the platform, but also its scalability and higher-throughput manufacturing in space.

The kidney and liver tissues were manufactured in support of research conducted by the Wake Forest Institute for Regenerative Medicine (WFIRM) using the institute’s cells and tissue designs. Auxilium provided the orbital manufacturing platform that enabled tissue fabrication in microgravity.

“This mission represents a significant milestone for both Auxilium and the future of space biomanufacturing,” said Jacob Koffler, PhD, MBA, CEO of Auxilium. “For the first time, we successfully bioprinted kidney and liver tissues in space, demonstrating that complex biological products can be manufactured in orbit. We also produced cartilage tissue and 28 nerve repair implants during the same mission using the same manufacturing platform. The ability to manufacture multiple tissue types alongside clinically relevant medical products highlights both the versatility and scalability of our technology. These results build on our previous demonstration of large-scale medical device manufacturing in space and represent another step toward establishing practical production capabilities for biomedical products beyond Earth.”

Dr. Anthony Atala, MD, Professor and Director of the Wake Forest Institute for Regenerative Medicine (WFIRM) commented, “Successfully bioprinting living liver and kidney tissue aboard the International Space Station marks an important step forward for regenerative medicine. The uniform cell distribution achieved aboard the space station points to real possibilities for manufacturing medical devices and tissues in space.”

Enabling the Next Generation of Biomedical Research

The successful bioprinting of kidney, liver, and cartilage tissues represents an important step toward enabling advanced biomedical research in space. One particularly promising application is the production of organoids, three-dimensional miniature tissue models that replicate key structural and functional characteristics of human organs. Organoids are increasingly used by researchers and pharmaceutical companies to study disease mechanisms, evaluate drug safety, screen new therapeutics, and predict responses to treatment.

Interest in organoid technologies has accelerated significantly as regulators and researchers seek more human-relevant alternatives to traditional animal testing. The U.S. Food and Drug Administration has identified organoids and other advanced tissue models as important components of its New Approach Methodologies initiative, while the National Institutes of Health has expanded efforts to advance and validate next-generation non-animal research platforms.

Today, organoids used for space-based research are manufactured on Earth and transported to orbit. The ability to manufacture these biological models directly in space could provide researchers with on-demand access to experimental systems while reducing dependence on launch schedules and Earth-based supply chains. As commercial space stations begin supporting larger research programmes, in-space production of organoids will create new opportunities for drug discovery, disease modelling, precision medicine, and human health research in microgravity.

By demonstrating the ability to manufacture multiple tissue types in orbit, Auxilium is helping establish the foundation for future space-based biomedical laboratories capable of producing advanced biological research tools whenever and wherever they are needed.

Source: Businesswire